Early Experience With Eravacycline for Complicated Infections
Sara Alosaimy, Kyle C. Molina, Kimberly C. Claeys, Justin Andrade, James Truong, Madeline King, Benjamin Pullinger, Glen Huang, Taylor Morrisette, Abdalhamid M Lagnf, Susan L. Davis, Michael J. Rybak
Abstract
Abstract Eravacycline (ERV) was used in 35 patients for various infections. The most common pathogen was Klebsiella pneumoniae, and 30-day survival was 74%. Absence of 30-day recurrence and resolution of signs and symptoms of infection were 91% and 57%, respectively. ERV was well-tolerated, with adverse events leading to drug discontinuation in one patient.
Topics & Concepts
MedicineDiscontinuationKlebsiella pneumoniaeAdverse effectPathogenic organismInternal medicineIntensive care medicineMicrobiologyBiochemistryGeneBiologyEscherichia coliChemistryAntibiotic Resistance in BacteriaDrug-Induced Adverse ReactionsPneumocystis jirovecii pneumonia detection and treatment